Back

Positive allosteric modulation of α5-GABA A Receptor in the 5XFAD mouse model has cognitive and neurotrophic benefits

Bernardo, A. M.; Marcotte, M.; Wong, K.; Sharmin, D.; Prandey, K.; Cook, J. M.; Sibille, E.; Prevot, T. D.

2022-10-03 pharmacology and toxicology
10.1101/2022.09.30.510361 bioRxiv
Show abstract

INTRODUCTIONReduced somatostatin (SST) and SST-expressing GABAergic neurons are well-replicated findings in Alzheimers disease (AD) and are associated with cognitive deficits. SST cells inhibit pyramidal cell dendrites through 5-GABA-A receptors (5-GABAA-R). 5-GABAAR positive allosteric modulation (5-PAM) has procognitive and neurotrophic effects in stress and aging models. METHODSWe tested whether 5-PAM (GL-II-73) could reverse cognitive deficits and neuronal spine loss in early and late stages of {beta}-amyloid deposition in the 5xFAD model (N=48/study; 50% female). RESULTSAcute or chronic administration of GL-II-73 reversed spatial working memory in 5xFAD mice at 2 and 5 months of age. Chronic GL-II-73 treatment reversed 5xFAD-induced loss of spine density, spine count and dendritic length at both time points, despite {beta}-amyloid accumulation. DISCUSSIONThese results demonstrate procognitive and neurotrophic effects of GL-II-73 in early and late stages of Alzheimer-related {beta}-amyloid deposition. This suggests 5-PAM as a novel {beta}-amyloid-independent symptomatic therapeutic approach.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Alzheimer's Research & Therapy
52 papers in training set
Top 0.1%
40.2%
2
The Journal of Prevention of Alzheimer's Disease
10 papers in training set
Top 0.1%
14.6%
50% of probability mass above
3
Alzheimer's & Dementia
143 papers in training set
Top 1.0%
6.5%
4
PLOS ONE
4510 papers in training set
Top 38%
3.7%
5
Neurobiology of Disease
134 papers in training set
Top 1%
3.7%
6
Journal of Alzheimer’s Disease
39 papers in training set
Top 0.4%
2.8%
7
International Journal of Neuropsychopharmacology
11 papers in training set
Top 0.1%
2.1%
8
Frontiers in Pharmacology
100 papers in training set
Top 2%
1.9%
9
ACS Chemical Neuroscience
60 papers in training set
Top 1%
1.7%
10
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.4%
1.7%
11
Alzheimer's & Dementia: Translational Research & Clinical Interventions
16 papers in training set
Top 0.3%
1.7%
12
Journal of Alzheimer's Disease
43 papers in training set
Top 0.8%
1.5%
13
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
38 papers in training set
Top 0.8%
1.2%
14
Frontiers in Aging Neuroscience
67 papers in training set
Top 2%
1.2%
15
Scientific Reports
3102 papers in training set
Top 70%
0.9%
16
Neurobiology of Aging
95 papers in training set
Top 2%
0.8%
17
Epilepsia
49 papers in training set
Top 0.7%
0.8%
18
Translational Psychiatry
219 papers in training set
Top 4%
0.7%
19
npj Aging
15 papers in training set
Top 1.0%
0.7%
20
Brain, Behavior, and Immunity
105 papers in training set
Top 3%
0.7%
21
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
62 papers in training set
Top 2%
0.5%
22
The Journals of Gerontology: Series A
25 papers in training set
Top 1%
0.5%
23
Biomedicine & Pharmacotherapy
43 papers in training set
Top 2%
0.5%